EMA Authorised: Ravicti (glycerol phenylbutyrate) — Immedica Pharma AB

View source ↗

Summary

The European Medicines Agency granted marketing authorization for Ravicti (glycerol phenylbutyrate) to treat inborn urea cycle disorders, with Immedica Pharma A…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urea Cycle Disorders

Drugs mentioned

• Ravicti (glycerol phenylbutyrate)

Snippet

Status: Authorised. Therapeutic area: Urea Cycle Disorders, Inborn. MAH: Immedica Pharma AB. Decision date: 05/12/2025. Orphan medicine